^
Association details:
| Biomarker: | ALK G1202R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/07/2021
Excerpt:
Non-Small Cell Lung Cancer...ALK REARRANGEMENT POSITIVE...SUBSEQUENT THERAPY...Lorlatinib (ALK G1202R)
Source:
Title:
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Excerpt:
...ALK G1202R resistance mutation), prior treatment with an ALK/ROS1 inhibitor is...
Trial ID:
Source:
Title:
1368P - Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program
Published date:
09/14/2020
Excerpt:
CONTRADICTING EVIDENCE: Patients with documented treatment failure of all approved ALK/ROS1-specific therapies (or with resistance mutations not covered by approved inhibitors or with leptomeningeal disease) and at least one other systemic treatment for metastatic NSCLC...Median duration of treatment with lorlatinib was 10.6 months (6.5-12.8)...G1202R/G2032R conferred a reduced PFS (4.1 vs. 11.0 months, p=0.04)...
Source:
Title:
Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
Published date:
05/28/2020
Excerpt:
The G1202R/Del mutation was detected in 23 pts samples; of which, 15 (65.2%) also harbored EML4-ALK variant 3. ORR was 33.3% (95% CI 16.5-54.0), 75.0% (95% CI 19.4-99.4) and 45.8% (95% CI 25.6-67.2) for variants 1, 2 and 3, respectively, while median DOR was similar for pts with variant 1 or 3 (both 6.9 months)...In this heavily pretreated group of ALK+ NSCLC pts, the presence of an ALK resistance mutation might enrich for EML4-ALK variants 1 and 3. Lorlatinib exhibited antitumor activity irrespective of EML4-ALK variant and across a variety of ALK resistance mutations.
DOI:
10.1158/1538-7445.AM2020-CT025
Test:
